Here, we evaluate whether a novel potent and long-lasting (t1⁄2 ≥7 hours) acylated α-CGRP analogue (αAnalogue) could alleviate and reverse cardiovascular disease in 2 distinct murine models of hypertension and heart failure in vivo. This evidence concerns the gene CALCA and cardiovascular disorder.